Home  »  Business   »  Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Have Decl...

Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Have Declined -21.62% YTD, Forecasting What Will Happen Next

Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s traded shares stood at 1.37 million during the last session. At the close of trading, the stock’s price was $3.77, to imply an increase of 2.45% or $0.09 in intraday trading. The AVIR share’s 52-week high remains $9.79, putting it -159.68% down since that peak but still an impressive 16.45% since price per share fell to its 52-week low of $3.15. The company has a valuation of $320.79M, with an average of 0.82 million shares in intraday trading volume over the past 10 days and average of 467.83K shares over the past 3 months.

Atea Pharmaceuticals Inc. (NASDAQ:AVIR) trade information

After registering a 2.45% upside in the last session, Atea Pharmaceuticals Inc. (AVIR) has traded red over the past five days. The stock hit a weekly high of 3.85 this Friday, 03/17/23, jumping 2.45% in its intraday price action. The 5-day price performance for the stock is 12.87%, and -7.82% over 30 days. With these gigs, the year-to-date price performance is -21.62%. Short interest in Atea Pharmaceuticals Inc. (NASDAQ:AVIR) saw shorts transact 1.48 million shares and set a 4.22 days time to cover.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Atea Pharmaceuticals Inc. (AVIR) estimates and forecasts

Looking at statistics comparing Atea Pharmaceuticals Inc. share performance against respective industry, we note that the company has underperformed competitors. Atea Pharmaceuticals Inc. (AVIR) shares are -44.96% down over the last 6 months, with its year-to-date growth rate lower than industry average at -46.04% against 9.60%. Revenue is forecast to shrink -133.60% this quarter before falling -2.00% for the next one.

AVIR Dividends

Atea Pharmaceuticals Inc. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Atea Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s Major holders

Atea Pharmaceuticals Inc. insiders hold 9.11% of total outstanding shares, with institutional holders owning 70.36% of the shares at 77.41% float percentage. In total, 70.36% institutions holds shares in the company, led by FMR, LLC. As of Sep 29, 2022, the company held over 12.49 million shares (or 14.99% of shares), all amounting to roughly $71.06 million.

The next major institution holding the largest number of shares is Blackrock Inc. with 7.87 million shares, or about 9.45% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $44.79 million.

We also have Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Atea Pharmaceuticals Inc. (AVIR) shares. Going by data provided on Nov 29, 2022, Fidelity Growth Company Fund holds roughly 3.03 million shares. This is just over 3.64% of the total shares, with a market valuation of $14.22 million. Data from the same date shows that the other fund manager holds a little less at 2.25 million, or 2.71% of the shares, all valued at about 12.82 million.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts